Grant supports gene-editing research for rare metabolic diseases

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children’s Hospital of Philadelphia (CHOP).

Biogen loses CMO, neuromuscular leader; John Hood adds president, CFO at Endeavor BioMedicines

→ Biogen chief medical officer Maha Radhakrishnan is out after four years “as of March 1,” a spokesperson tells Peer Review. Biogen didn’t draw up

March 16, 2024

Extracellular vesicles may drive fibrosis in scleroderma

Extracellular vesicles, responsible for cell-to-cell communication, might be a driver of fibrosis in systemic sclerosis, according to a recent paper in Arthritis and Rheumatology.

July 21, 2023

Lundbeck acquires all outstanding shares of Longboard

The acquisition provides Lundbeck access to bexicaserin, a 5-HT2C agonist. Credit: Longfin Media/Shutterstock. Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals,

December 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.